PrECOG Cancer Research Group
Innovative cancer research studies developed through industry partnerships and networks.
Supporting ECOG-ACRIN Cancer Research Group's efforts to advance cancer care
06/01/2026
How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in a clinical trial? The PrE1702 research study aims to find out. Learn more: https://bit.ly/pre1702-study
05/29/2026
Dr. Taofeek Owonikoko of is leading PrE0510, a phase 2 clinical trial treating patients with extensive-stage small cell lung cancer ( ) who have not yet had systemic therapy. Learn more: https://bit.ly/PrE0510
05/25/2026
The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study
05/22/2026
The PrE0510 clinical trial, led by Dr. Taofeek Owonikoko of , aims to determine the optimal dose of ivonescimab in combo with carboplatin & etoposide for patients with small cell lung cancer. More: https://bit.ly/PrE0510
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
1818 Market Street, Suite 3000
Philadelphia, PA
19118
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |